AUA Advanced Prostate Cancer Course Webcast (2025)
This course will be focused on comprehensive AUA/SUO Guidelines on APC in the management and outcomes of men with biochemical recurrence, locally advanced, metastatic HSPC and CRPC. The course will include risk stratification, germline testing, PET imaging, the use of ADT in combination with novel androgen axis therapy and chemotherapy in men with newly diagnosed advanced and mHSPC. Early treatment intensification and evidenced based guidelines will be covered. The course will also cover non-metastatic CRPC, and treatment for mCRPC. The use of sequencing, combination therapy, somatic testing and precision medicine with PARP inhibitors will also be discussed. The course will also cover emerging combination and precision-based therapies for CRPC.
ACKNOWLEDGEMENTS:
This educational activity is supported by independent educational grants from:
Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.
Learning Objectives
At the conclusion of this activity, participants will be able to:
- Describe appropriate use of genetic testing (germline) and understand the importance of genetic counseling.
- Describe appropriate use of somatic testing and treatments related to specific genetic alterations.
- Identify appropriate combination therapy with ADT plus novel androgen access therapies and chemotherapy. Early treatment intensification including patient selection and adverse effects and benefits will be discussed in mHSCPC.
- Explain the treatments for non-metastatic CRPC and oncologic outcomes, with recommendations based on AUA/SUO Guidelines.
- Counsel patients on available treatment options for CRPC as well as combination therapy and sequencing based on the latest AUA/SUO Guidelines.
FACULTY DISCLOSURES
Name | Company Name | Relationship Type | End Date |
Cookson, Michael S. | Pfizer | Consultant or Advisor | Current |
Nonagen Bioscience Corp. | Consultant or Advisor | 07/11/2023 | |
Progenics Phamaceuticals, Inc. (Lanthues) | Consultant or Advisor | Current | |
Bayer | Consultant or Advisor | Current | |
Jarrard, David F. | No relevant financial relationships to disclose | ||
Kibel, Adam S. | Janssen | Consultant or Advisor | Current |
Bristol-Myers Squibb | Other-Data Safety Monitoring Board | Current | |
Pfizer | Consultant or Advisor | 05/02/2023 | |
Merck | Consultant or Advisor | 11/17/2024 | |
Lowrance, William Thomas | No relevant financial relationships to disclose |
EDUCATION COUNCIL DISCLOSURE
Education Council Disclosures_June 2024.pdf
COI REVIEW WORK GROUP DISCLOSURES
COI Review Workgroup Disclosures_June 2024.pdf
AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.
ACCREDITATION INFORMATION
Method of Participation: Learners will participate in this online educational activity by viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.
Release Date: May, 2025
Expiration Date: May, 2026
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.
Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
AUA PARTICIPANT INFORMATION & POLICIES
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
Available Credit
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation